Vanzacaftor - Vertex Pharmaceuticals
Alternative Names: Vanzacaftor; VX 121Latest Information Update: 25 Sep 2025
At a glance
- Originator Vertex Pharmaceuticals
- Class Antifibrotics; Ethers; Heterocyclic compounds with 4 or more rings; Pyrazoles; Pyridines; Pyrrolidines; Small molecules; Spiro compounds
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 25 Sep 2025 Discontinued - Phase-I for Cystic fibrosis (Monotherapy, In volunteers, In adults) in USA (PO) (Vertex Pharmaceuticals Pipeline, September 2025)
- 25 Sep 2025 Discontinued - Phase-I/II for Cystic fibrosis (Combination therapy) in Netherlands (PO) (Vertex Pharmaceuticals Pipeline, September 2025)
- 25 Sep 2025 Discontinued - Phase-I/II for Cystic fibrosis (Monotherapy) in Netherlands (PO) (Vertex Pharmaceuticals Pipeline, September 2025)